skip to main content
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

16 Total results for product and free and sample content found

Datamonitor Healthcare, Biomedtracker, Pharma...

2019 Q3 Outlook Webinar

By Hardik Patel 15 Jul 2019

Pharma Intelligence presents an essential, free session during which industry analysts present their data-driven views about what to expect during the third quarter of 2019. 

Topic immuno-oncology Infectious Diseases

Scrip

Gilead Says 16 Cancer Centers Getting Ready To Administer Yescarta

By Joseph Haas 31 Oct 2017

Gilead Says 16 Cancer Centers Getting Ready To Administer Yescarta

Within weeks of its acquisition of Kite, Gilead is working to launch its first immuno-oncology drug, with a goal of training.

Topic immuno-oncology

Datamonitor Healthcare

Immuno-Oncology Overview

By Colin White, Robert Jeng & Jolene Lau 19 Sep 2017

Immuno-Oncology Overview

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well

Topic immuno-oncology

Datamonitor Healthcare

PD-1/PD-L1 Inhibitors: The First Wave of Immuno-Oncology

By Dustin Phan 17 Sep 2017

PD-1/PD-L1 Inhibitors: The First Wave of Immuno-Oncology

Recently, Informa Pharma Intelligence conduced an insightful webinar regarding the current market landscape and outlook for immuno-oncology.

Topic immuno-oncology

Scrip

BMS' Opdivo Approval In CRC Overshadowed By Keytruda Dominance

02 Aug 2017

BMS' Opdivo Approval In CRC Overshadowed By Keytruda Dominance

The US FDA has approved BMS' Opdivo for previously treated patients with some forms of colorectal cancer, however direct competition from Merck's Keytruda may limit its success.

Topic immuno-oncology Cancer

Scrip

PD-1 Data Emerges In Cervical Cancer

By Lucie Ellis 26 Jul 2017

PD-1 Data Emerges In Cervical Cancer

Leading immunotherapy agents are beginning to report early-stage data from monotherapy and combination trials in advanced cervical cancer – a treatment area with very few approved options.

Topic Cancer immuno-oncology Research & Development Strategy

Scrip

Immuno-Oncology Outlook: Getting To The Root Of Head And Neck Cancer

24 Jul 2017

Immuno-Oncology Outlook: Getting To The Root Of Head And Neck Cancer

As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.

Topic Cancer immuno-oncology

Scrip

Boehringer Ingelheim's Partnering Focus: An Interview With Ioannis Sapountzis

By Joseph Haas 04 Jul 2017

Boehringer Ingelheim's Partnering Focus: An Interview With Ioannis Sapountzis

Trying to catch up with peers in both immuno-oncology and NASH, the German pharma has assigned Sapountzis to lead its US business development efforts.

Topic Cancer immuno-oncology

Pink Sheet

Immuno-oncology Drugs And The Trouble With Market Access

By Francesca Bruce 06 Jun 2017

Immuno-oncology Drugs And The Trouble With Market Access

The clinical potential of immuno-oncology drugs does not seem to be reflected in approaches by health technology assessment bodies, with different interpretations of data.

Topic immuno-oncology

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: